Hepatitis C virus (HCV) is a hepatotropic virus and a major cause of chronic hepatitis and
liver disease worldwide. Initial interactions between HCV virions and hepatocytes are …

Hepatitis C virus (HCV) is a blood borne disease estimated to chronically infect 3% of the
worlds' population causing significant morbidity and mortality. Current medical therapy is …

In contrast to a detailed understanding of antiviral cellular immune responses, the impact of
neutralizing antibodies for the resolution of acute hepatitis C is poorly defined. The analysis …

The contribution of humoral immune responses to spontaneous control of hepatitis C virus
(HCV) infection remains unclear. We assessed neutralizing antibody (nAb) responses …

Hepatitis C virus (HCV) remains a significant threat to the general health of the world's
population, and there is a pressing need for the development of new treatments and …

Cellular binding and entry of hepatitis C virus (HCV) are the first steps of viral infection and
represent a major target for antiviral antibodies and novel therapeutic strategies. We have …

Hepatitis C virus (HCV), an important human pathogen, is an enveloped, positive-stranded
RNA virus classified in the hepacivirus genus of the Flaviviridae family. Cell attachment of …

With an estimated 170 million infected individuals, hepatitis C virus (HCV) has a major
impact on public health. A vaccine protecting against HCV infection is not available, and …

Hepatitis C virus (HCV) remains a global problem, despite advances in treatment. The low
cost and high benefit of vaccines have made them the backbone of modern public health …

The introduction of directly acting antiviral agents (DAAs) has produced significant
improvements in the ability to cure chronic hepatitis C infection. However, with over 2% of …